Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-699-2 | CAS number: 109-73-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
n-Butylamine is corrosive. A concentration dependent increase in incidence and severity of changes in the epithelium of the anterior nasal cavity occurred. The LOAEC local for irritation of the upper respiratory tract was 51 mg/m³ (17 mL/m³).
However, no treatment related clinical findings were observed up to the highest concentration so that a NOAEC of 460 mg/m³ could be derived for systemic effects.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- OECD 414 guideline study which does not address all aspects relevant for repeated dose toxicity
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- yes
- Remarks:
- according to OECD Guideline 414 (Prenatal Developmental Toxicity Study) [see 7.8.2]
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: K. Thomae GmbH/Boehringer Ingelheim, Biberach/Germany
- Age at study initiation: approx. 70 d
- Weight at study initiation: 198 - 246 g
- Housing: single
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 d before mating
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus:glass-steel inhalation exposure chamber, 1.4 m3, space for 6x6 cages
- Method of holding animals in test chamber: 1 animal/cage
- Source and rate of air: charcoal-filtered air
- System of generating particulates/aerosols: In a thermostated vaporiser (25 - 35 °C), the vapor-air mixture was generated by spraying the TS
with compressed air into a counter current of conditioned air, followed by further mixing with air to achieve required
exposure concentrations.
- Temperature, humidity, pressure in air chamber: 21.2 - 22.5 °C; 50.5 - 62.0 %
- Air change rate: Air changes: 20/hour
TEST ATMOSPHERE
- Brief description of analytical method used: GC/FID after absorption in DMF
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Method: GC with FID detection
- Sampling time: 2 times during each exposure (for controls 2 times during the study) - Duration of treatment / exposure:
- 14 d (6 - 19 day of gestation)
- Frequency of treatment:
- 6 h/d
- Remarks:
- Doses / Concentrations:
51.4 +-2.2; 151.8 +-9.2; and 460 +-17.5 mg/m3 (= 17, 50.1, and 151.8 ml/m3)
Basis:
analytical conc. - No. of animals per sex per dose:
- 20 - 24 pregnant female rats
- Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: 3x during exposure, other days 1x
BODY WEIGHT: Yes
- Time schedule for examinations: on day 1, 3, 6, 8, 10, 13, 15, 17, 19 and 20
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: ovary, uterus, placenta
- macroscopy of dams
- histopathological examination of 4 sections of the nasal cavity - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- - Mortality: none
- Body weight: no treatment related effects
- Clinical signs: no treatment related effects
- Gross pathology incidence and severity: no treatment related effects [incidental congestion, oedema and/or marginal emphysema
of the lungs (due to method of sacrifice)]
- Histopathology incidence and severity: anterior nasal section showing squamous metaplasia, inflammatory cells and hyperplasia of
transitional cells at all concentrations (dose dependent effect). At 450 mg/m3, necrosis of the nasal mucosa (5 animals) and the underlying
nasal bone (1 animal). - Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 51 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: local effects (nasal irritation)
- Dose descriptor:
- NOAEC
- Effect level:
- < 51 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: local effects (nasal irritation)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 460 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: systemic toxicity
- Key result
- Critical effects observed:
- not specified
- Conclusions:
- Under the conditions of this study, the LOAEC for irritation of the upper respiratory tract was 51 mg/m3. In the absence of systemic toxicity a NOAEC of 460 mg/m3 can be determined.
- Executive summary:
Twenty-five mated female Wistar rats per test group were whole-body exposed to dynamic atmospheres of Mono-n-Butylamin vapors for 6 hours per day on day 6 through day 19 post coitum (p.c.; 14 exposures). The target concentrations were 50, 150 and 450 mg/m 3. A concurrent control group was exposed to clean air.
No treatment related clinical findings were observed. A concentration dependent increase in incidence and severity of changes in the epithelium of the anterior nasal cavity (necrosis, hyper- and metaplasia, inflammatory cell infiltration) occurred. Under the conditions of this prenatal developmental toxicity study, the inhalation exposure of pregnant Wistar rats to vapours of Mono-n-Butylamin from implantation to one day prior to the expected day of parturition (days 6 - 19 p.c.) elicited maternal toxicity at all tested concentrations. Maternal toxicity was substantiated by changes of the respiratory epithelium in the nasal cavity.
Reference
Nasal irritation in dams following inhalation exposure to n-butylamine during gestation (14 d):
Percentage of dams (n = 10) showing lesions exposed to the following concentrations in ppm [mg/m3], nominal |
||||
Histopathological findings |
0 |
17 [50] |
50 [150] |
150 [450] |
Squamous cell metaplasia |
0 |
10 |
50 |
100 |
Purulent to mixed inflammatory cell infiltration |
0 |
30 |
90 |
100 |
Focal necrosis of nasal mucosa |
0 |
0 |
0 |
50 |
Necrosis of nasal bone |
0 |
0 |
0 |
10 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEC
- 460 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Repeated dose toxicity was examined in the context of a developmental toxicity study and the data was considered sufficient for evaluation of this endpoint (see below).
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- OECD 414 guideline study which does not address all aspects relevant for repeated dose toxicity
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- yes
- Remarks:
- according to OECD Guideline 414 (Prenatal Developmental Toxicity Study) [see 7.8.2]
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: K. Thomae GmbH/Boehringer Ingelheim, Biberach/Germany
- Age at study initiation: approx. 70 d
- Weight at study initiation: 198 - 246 g
- Housing: single
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 d before mating
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus:glass-steel inhalation exposure chamber, 1.4 m3, space for 6x6 cages
- Method of holding animals in test chamber: 1 animal/cage
- Source and rate of air: charcoal-filtered air
- System of generating particulates/aerosols: In a thermostated vaporiser (25 - 35 °C), the vapor-air mixture was generated by spraying the TS
with compressed air into a counter current of conditioned air, followed by further mixing with air to achieve required
exposure concentrations.
- Temperature, humidity, pressure in air chamber: 21.2 - 22.5 °C; 50.5 - 62.0 %
- Air change rate: Air changes: 20/hour
TEST ATMOSPHERE
- Brief description of analytical method used: GC/FID after absorption in DMF
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Method: GC with FID detection
- Sampling time: 2 times during each exposure (for controls 2 times during the study) - Duration of treatment / exposure:
- 14 d (6 - 19 day of gestation)
- Frequency of treatment:
- 6 h/d
- Remarks:
- Doses / Concentrations:
51.4 +-2.2; 151.8 +-9.2; and 460 +-17.5 mg/m3 (= 17, 50.1, and 151.8 ml/m3)
Basis:
analytical conc. - No. of animals per sex per dose:
- 20 - 24 pregnant female rats
- Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: 3x during exposure, other days 1x
BODY WEIGHT: Yes
- Time schedule for examinations: on day 1, 3, 6, 8, 10, 13, 15, 17, 19 and 20
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: ovary, uterus, placenta
- macroscopy of dams
- histopathological examination of 4 sections of the nasal cavity - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- - Mortality: none
- Body weight: no treatment related effects
- Clinical signs: no treatment related effects
- Gross pathology incidence and severity: no treatment related effects [incidental congestion, oedema and/or marginal emphysema
of the lungs (due to method of sacrifice)]
- Histopathology incidence and severity: anterior nasal section showing squamous metaplasia, inflammatory cells and hyperplasia of
transitional cells at all concentrations (dose dependent effect). At 450 mg/m3, necrosis of the nasal mucosa (5 animals) and the underlying
nasal bone (1 animal). - Key result
- Dose descriptor:
- LOAEC
- Effect level:
- 51 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: local effects (nasal irritation)
- Dose descriptor:
- NOAEC
- Effect level:
- < 51 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: local effects (nasal irritation)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 460 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: systemic toxicity
- Key result
- Critical effects observed:
- not specified
- Conclusions:
- Under the conditions of this study, the LOAEC for irritation of the upper respiratory tract was 51 mg/m3. In the absence of systemic toxicity a NOAEC of 460 mg/m3 can be determined.
- Executive summary:
Twenty-five mated female Wistar rats per test group were whole-body exposed to dynamic atmospheres of Mono-n-Butylamin vapors for 6 hours per day on day 6 through day 19 post coitum (p.c.; 14 exposures). The target concentrations were 50, 150 and 450 mg/m 3. A concurrent control group was exposed to clean air.
No treatment related clinical findings were observed. A concentration dependent increase in incidence and severity of changes in the epithelium of the anterior nasal cavity (necrosis, hyper- and metaplasia, inflammatory cell infiltration) occurred. Under the conditions of this prenatal developmental toxicity study, the inhalation exposure of pregnant Wistar rats to vapours of Mono-n-Butylamin from implantation to one day prior to the expected day of parturition (days 6 - 19 p.c.) elicited maternal toxicity at all tested concentrations. Maternal toxicity was substantiated by changes of the respiratory epithelium in the nasal cavity.
Reference
Nasal irritation in dams following inhalation exposure to n-butylamine during gestation (14 d):
Percentage of dams (n = 10) showing lesions exposed to the following concentrations in ppm [mg/m3], nominal |
||||
Histopathological findings |
0 |
17 [50] |
50 [150] |
150 [450] |
Squamous cell metaplasia |
0 |
10 |
50 |
100 |
Purulent to mixed inflammatory cell infiltration |
0 |
30 |
90 |
100 |
Focal necrosis of nasal mucosa |
0 |
0 |
0 |
50 |
Necrosis of nasal bone |
0 |
0 |
0 |
10 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEC
- 51 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Effects in the upper respiratory tract (the most sensitive target) were observed at the lowest exposure concentration.
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
In the absence of any information on species specific modes of action the available information is regarded as relevant for humans.
Additional information
The most appropriate route of exposure is inhalation. There is no guideline repeated dose toxicity study, e.g. according to OECD guidelines 412, 413, available.
However, information is available from a developmental study (BASF AG 2001/2002), which is suitable to assess the inhalation toxicity and was selected therefore as key study:
The most relevant effect of n-butylamine is its irritating/corrosive effect on skin and mucous membranes. Effects in the upper respiratory tract (the most sensitive target) were observed at the lowest exposure concentration of 51 mg/m3 in the developmental study (BASF AG 2001/2002) already after 14 days of exposure.
Effects in other organs were not examined, but the absence of systemic responses at this and even higher exposure concentration can be reasonably assumed:
1) As the amines are readily metabolised to biogenic molecules, e.g. butyric acid, systemic effects are not assumed to occur at concentrations which already provoke irritation.
2) A calculation of resulting body doses of the highest exposure concentration (inhalation) with an oral study with pregnant rats receiving the hydrochloride salt of butylamine (see Developmental toxicity, IUCLID 7.8.2) confirm this assumption: An exposure of rats to 460 mg/m3 (6 h/d; analytical), which is severely irritating, corresponds to a body dose of 450 mg/m3 x 0.29 m3/kg bw = 130.5 mg/kg bw (caluclation according to ECHA guidance R.8). The maternal NOAEL in the oral study was 460 mg/kg bw/d hydrochloride, corresponding to 265 mg/kg bw/d amine base, i.e. a factor of about 2 higher than the highest body dose resulting from inhalation exposure.
Therefore, no systemic effects are expected at inhalation concentrations up to 460 mg/m3 (6 h/d; analytical), the highest test concentration in the inhalation study, and a fortiori not at the LOAEC for irritation of 51 mg/m3.
Justification for classification or non-classification
Classification with respect to STOT RE endpoints for maternal effects in a developmental toxicity study according to Regulation (EC) No 1272/2008 is not necessary, as no systemic toxic effects were observed after repeated exposure in a developmental toxicity study (14 exposures). The only effects observed were local effects in the respiratory tract which are already considered in the STOT SE 3 classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.